関節リウマチ治療における生物学的製剤の選択と適正使用

出版社： 日本医学出版
著者：
発行日： 2015-03-10
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784865770032
電子書籍版： 2015-03-10 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,300 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,300 円(税込)

購入する

商品紹介

関節リウマチ治療における生物学的製剤の選択と適正使用のナビゲーションを目標として、関節リウマチ治療の基本的な考え方、生物学的製剤の基礎知識、他の薬剤との併用や処方の実際について、第一線で活躍中の医師36名が執筆。実臨床に役立てて頂き、リウマチ医療の心髄に触れて頂きたい。

目次

  • 関節リウマチ治療における生物学的製剤の選択と適正使用

    ―目次―

    第１章　生物学的製剤―選択と適正使用の実際
    １　生物学的製剤の分類と特徴
    ２　関節リウマチ治療における生物学的製剤の適応と治療戦略
    ３　関節リウマチ治療における生物学的製剤の治療効果
    ４　関節リウマチ治療における生物学的製剤効果
    　　　減弱例における他剤への切り替え
    ５　関節リウマチ治療における生物学的製剤の副作用・相互作用
    　　　―感染症、悪性腫瘍、脱髄疾患など―

    第２章　関節リウマチ治療における各種生物学的製剤の基礎知識
    １　インフリキシマブ
    ２　エタネルセプト
    ３　アダリムマブ
    ４　トシリズマブ
    ５　アバタセプト
    ６　ゴリムマブ
    ７　セルトリズマブ　ペゴル
    ８　開発中の生物学的製剤

    第３章　関節リウマチにおける生物学的製剤と他の薬剤との併用
    １　生物学的製剤と抗リウマチ薬（DMARDｓ）
    ２　生物学的製剤とステロイド
    ３　生物学的製剤と非ステロイド抗炎症薬（NSAIDｓ）
    ４　バイオシミラー
    ５　生物学的製剤の休薬の可能性
    ６　生物学的製剤と人工関節
    ７　医療経済と生物学的製剤

    第４章　関節リウマチにおける生物学的製剤処方事例
    １　インフリキシマブ
    ２　エタネルセプト
    ３　アダリムマブ
    ４　トシリズマブ
    ５　アバタセプト
    ６　ゴリムマブ
    ７　セルトリズマブ

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 生物学的製剤 - 選択と適正使用の実際

P.5 掲載の参考文献
1) Smolen JS, Aletaha D, Bijlsma JWJ, et al : Treating rheumatoid arthritis to target : recommendations of an international task force. Ann Rheum Dis (2010) 69, 631-637
 
2) Lipsky PE : Rheumatoid arthritis, 18th edition, (eds. By Fauci AS, Braunwald E, Kasper DL, et al), McGraw-Hill, Columbus 2011 ; p2738-A52
 
3) Felson DT, Smolen JS, Wells G, et al : American college of rheumatology/european league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 70 : 404-413
 
4) Singh JA, Furst DE, Bharat A, et al : 2012 update of the 2008 american college of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (2012) 64 : 625-639
 
5) Weinblatt ME, Bathon JM, Kremer JM, et al : Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and long-standing rheumatoid arthritis. Arthritis Care Res Arthritis Care Res (2011) 63, 373-382
 
6) Tanaka Y : Next stage of RA treatment : is TNF inhibitor-free remission a possible treatment goal? Ann Rheum Dis (2012) 72 suppl 2 : ii 124-127
 
7) Tanaka Y : Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol (2012) 24 : 319-326
 
8) Koike T, Harigai M, Inokuma S, et al : Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol (2009) 36 : 898-906
 
P.10 掲載の参考文献
1) van Doornum S, McColl G, Wicks IP : Accellerated atherosclerosis. An extraarticular feature of rheumatoid arthrirtis? Arthritis Rheum, 2002 ; 46 : 862.
 
2) Pincus T, Callahan LF : Taking mortality in rheumatoid arthritis seriously. Predictive markers, socioeconomic status and comorbidity. J Rheumatol, 1986 ; 13 : 841.
PubMed
3) Aletaha D, Neogi T, Silman AJ, et al : 2010 Rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum, 2010 : 62 ; 2569-2581.
PubMed
4) 日本リウマチ学会 関節リウマチに対するTNF阻害薬使用ガイドライン (2014年改訂版) http://www.ryumachi-jp.com/info/guideline_TNF.html
 
5) Singh JA, Furst DE, Bharat A, et al : 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res., 2012, 64 : 625-639.
PubMed
6) Smolen JS, Landewe R, Breedveld FC, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying an-tirheumatic drugs. 2013 update Ann Rheum Dis (2014) 73 : 492-509
 
7) 関節リウマチ診療ガイドライン2014 : 日本リウマチ学会編集. メディカルレビュー社. 2014.
 
8) Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF, et al : Comparison of treatment strategies in early rheumatoid arthritis : a randomized controlled trial. Ann Intern Med, 2007 ; 146 : 406-415.
PubMed
9) Felson DT, Smolen JS, Wells G, Zhang B, et al : American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis. Arthritis Rheum, 2011 ; 63 : 573-586.
PubMed
P.16 掲載の参考文献
1) Maini RN et al : Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (9) : 1552-1563, 1998.
PubMed
2) Lpsky PE et al : Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (22) : 1594-1602, 2000.
 
3) St Clair EW et al : Combination of infliximab and methotrexate therapy for early rheumatoid arthritis : a randomized, controlled trial. Arthritis Rheum 50 (11) : 3432-3443, 2004.
PubMed
4) Smolen JS et al : Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab : results from the ASPIRE trial. Arthritis Rheum 54 (3) : 702-710, 2006.
PubMed
5) Weinblatt ME et al : Atrial of etanercept, arecombinant tumor necrosis factor receptor : Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (4) : 253-259, 1999.
 
6) Bathon JM et al : A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343 (22) : 1586-1593, 2000.
PubMed
7) Klareskog L et al : Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomised controlled trial. Lancet 363 (9410) : 675-681, 2004.
PubMed
8) Weinblatt ME et al : Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate : the ARMADA trial. Arthritis Rheum 48 (1) : 35-45, 2003.
PubMed
9) Breedvelt F et al : The PREMIER study : A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (1) : 26-37, 2006.
 
10) Miyasaka N et al : Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation : the CHANGE study. Mod Rheumatol 18 (3) : 252-262, 2008.
PubMed
11) Bartelds GM et al : Clinical response to adalimumab : relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66 (7) : 921-926, 2007.
PubMed
12) Keystone EC et al : Golimumab, a human antibody to tumour necrosis factor｛alpha｝given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy : the GOFORWARD Study. Ann Rheum Dis 268 (6) : 789-796, 2009.
 
13) Emery P et al : Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis : twentyfour-week results of a phase III, multicenter, randomized, double-blind, placebocontrolled study of golimumab before methotrexate as first-line therapy for early. onset rheumatoid arthritis. Arthritis Rheum 60 (8) : 2272-2283, 2009.
 
14) Smolen JS et al : Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study) : a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374 (9685) : 210-221, 2009.
PubMed
15) Tanaka Y et al : Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis : results of the GO-FORTH study. Ann Rheum Dis 71 (6) : 817-824, 2012.
PubMed
16) Takeuchi T et al : Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs : results of the phase 2/3, multicentre, randomised, double-blind, placebocontrolled GO-MONO study through 24 weeks. Ann Rheum Dis 72 (9) : 1488-1495, 2013.
PubMed
17) Keystone E et al : Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis : findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo. controlled, parallel-group study. Arthritis Rheum 58 (11) : 3319-3329, 2008.
 
18) Smolen J et al : Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis : the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 68 (6) : 797-804, 2009.
PubMed
19) Fleischmann R et al : Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy : the FAST4-WARD study. Ann Rheum Dis 68 (6) : 805-811, 2009.
 
20) Nishimoto N et al : Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI) : significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 19 (1) : 12-19, 2009.
 
21) Nishimoto N et al : Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI) : evidence of clinical and radiographic beneelit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 (9) : 1162-1167, 2007.
 
22) Maini RN et al : Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (9) : 2817-2829, 2006.
PubMed
23) Smolen JS et al : Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Lancet. 371 (9617) : 987-997, 2008.
PubMed
24) Genovese MC et al : Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs : the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58 (10) : 2968-2980, 2008.
PubMed
25) Emery P et al : IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals : results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67 (11) : 1516-1523, 2008.
PubMed
26) Jones G et al : Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis : the AMBITION study. Ann Rheum Dis 69 (1) : 88-96, 2010.
PubMed
27) Kremer JM et al : Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate : results from the doubleblind treatment phase of a randomized placebo*controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 63 (3) : 609-621, 2011.
PubMed
28) Moreland I-W et al : Costimulatory blockade in patients with rheumatoid arthritis : a pilot, dose-finding, double-blind, Placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arhritis Rheum 46 (6) : 1470-1479, 2002.
 
29) Kremer JM et al : Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis : a randomized trial. Ann Intern Med 144 (12) : 865-876, 2006.
PubMed
30) Kremer JM et al : Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58 (4) : 953-963, 2008.
PubMed
31) enant HK et al : Abatacept inhibits structural damage progression in rheumatoid arthritis : results from the long-term extension of the AIM trial. Ann Rheum Dis 67 (8) : 1084-9, 2008.
 
32) Genovese MC et al : Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353 (11) : 1114-1123, 2005.
PubMed
33) Weinblatt M et al : Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept : arandomised clinical trial. Ann Rheum Dis 66 (2) : 228-234, 2007.
PubMed
34) Goekoop-Ruiterman YP et al : Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the Best study) : a randomized, controlled trial. Arthritis Rheum 52 (11) : 3381-3390, 2005.
PubMed
35) Tanaka Y et al : Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69 (7) : 1286-1291, 2010.
PubMed
P.23 掲載の参考文献
1) van Schouwenburg PA, et al : Immunogenecity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013 ; 9 : 164-72
 
2) Miyasaka N, et al : Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation : CHANGE study. Mod Rheumatol 2008 ; 18 : 252-262
 
3) Takeuchi T, et al : Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis : results from the RISING study. Mod Rheumatol 2009 ; 19 : 478-487
 
4) Atzeni F, et al : Switching rheumatoid arthritis treatments : An update. Autoim. mun Rev 2011 ; 10 : 397-403
 
5) Pascual-Salcedo D, et al : Influence of immunogenicity on the efficacy of long-term treatment with in fliximab in rheumatoid arthritis. Rheumatology 2011 ; 50 : 1445-1452
 
6) Finckh A, et al : Evidence for differential acquired drug resistance to anti-tumor necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006 ; 65 : 746-752
 
7) Nishimoto N, et al : Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study) : evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009 ; 68 : 1580-1584
 
8) Hyrich KL, et al : Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis : results from a large UK national cohort study. Arthritis Rheum 2007 ; 56 : 13-20
 
9) Virkki LM, et al : Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based orl observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol 2011 ; 30 : 1447-1454
 
10) Jamnitski A, et al : The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011 ; 70 : 284-288
 
11) Takeuchi T, et al : Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. Rheumatology (Oxford). 2011 ; 50 : 1908-1915
 
12) Emery P, Keystone E, Tony HP, et al : IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals : results from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis 2008 ; 67 : 1516-1523
 
13) Genovese MC, et al : Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005 ; 353 : 1114-1123
 
14) Schiff M, et al : Clinical response and tolerability to abatacept in patients with heumatoid arthritis previously treated with infliximab or abatacept : open-label extension of the ATTEST Study. Ann Rheum Dis 2011 ; 70 : 2003-2007
 
15) Leffers HC, et al : Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice : results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011 ; 70 : 1216-1222
 
P.30 掲載の参考文献
1) Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, Amano K, Nakajima A, Atsumi T, Koike T et al : Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64 (8) : 1125-1134.
PubMed
2) Askling J, Fored CM, Brandt I., Baecklund E, Bertilsson I., Feltelius N, Coster L, Geborek P, Jacobsson LT, Lindblad S et al : Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007, 66 (10) : 1339-1344.
 
3) Harigai M, Koike R, Miyasaka N : Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007, 357 (18) : 1874-1876.
PubMed
4) Koike R, Takeuchi T, Eguchi K, Miyasaka N : Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007, 17 (6) : 451-458.
PubMed
5) 持田智 : 免疫抑制薬, 抗悪性腫瘍薬によるB型肝炎ウイルス再活性化の実態解明と対策法の確立研究. 厚生労働科学研究費補助金肝炎等克服緊急対策研究事業, 平成23年度研究成果報告書. 2011. p61.
 
6) 小池隆夫, 針谷正祥, 三村俊英, ほか : B型肝炎ウイルス感染リウマチ性疾患患者への免疫抑制療法に関する提言
 
7) Smitten AL, Simon TA, Hochberg MC, Suissa S : A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10 (2) : R45.
PubMed
8) Harigai M, Nanki T, Koke R, et al : Biological Agents in Rheumatoid Arthritis and Risk of Malignancy-Results from the Nation-Wide Cohort Study in Japan. [abstract] : ACR2011, Chicago, USA.
 
9) Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN : Demyelination occurring during anti. tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44 (12) : 2862-2869.
PubMed
10) Simsek I, Erdem H, Pay S, Sobaci G, Dinc A : Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2007, 66 (9) : 1255-1258.
PubMed
11) Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN : Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006, 54 (5) : 1429-1434.
 
12) Eguren C, Diaz I. ey B, Dauden E, Garcia-Diez A, Losada M : Peripheral neuropathy in two patients with psoriasis in treatment with infliximab. Muscle Nerve 2009, 40 (3) : 488-489.
 
13) Kobayashi K, Okamoto Y, Inoue H, Usui T, Ihara M, Kawamata J, Miki Y, Mimori T, Tomimoto H, Takahashi R : Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med 2009, 48 (15) : 1307-1309.
PubMed
14) Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M : Pharmacokinetics, pharmacodynamics and physiologicallybased pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 2013, 52 (2) : 83-124.
PubMed
15) Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E : Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs : A one-year randomized, placebocontrolled study. Arthritis Rheum 2006, 54 (9) : 2807-2816.
PubMed
16) Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN et al : Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41 (9) : 1552-1563.
PubMed
17) Adalimumab [package insert]. North Chicago, II. : Abbott Laboratories ; 2012
 
18) ゴリムマブ承認審査概要 9. 臨床概要 p23-p24.
 
19) Mould DR, Sweeney KR : The pharmaco. kinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007, 10 (1) : 84-96.
 
20) Tabrizi MA, Tseng CM, Roskos LK : Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006, 11 (1-2) : 81-88.
 
21) Listing J, Pattloch D, Kekow J, et al : Successful control of disease activity and treatment with biologics increase the life expectancy in rheumatoid arthritis patients [abstract] ; EULAR2012, Berlin, Germany.
 

第2章 関節リウマチ治療における各種生物学的製剤の基礎知識

P.37 掲載の参考文献
1) Lipsky, P. E., D. M. van der Heijde, E. W. St Clair, D. E. Furst, F. C. Breedveld, J. R. Kalden, J. S. Smolen, M. Weisman, P. Emery, M. Feldmann, G. R. Harriman, and R. N. Maini : Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000 ; 343 : 1594-1602.
 
2) Maini, R. N., F. C. Breedveld, J. R. Kalden, J. S. Smolen, D. Furst, M. H. Weisman, E. W. St Clair, G. F. Keenan, D. van der Heijde, P. A. Marsters, and P. E. Lipsky : Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004 ; 50 : 1051-1065.
 
3) Takeuchi, T., N. Miyasaka, K Inoue, T. Abe, and T. Koike : Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis : results from the RISING study. Mod Rheumatol 2009 ; 19 : 478-487.
 
4) van Vollenhoven, R. F., E. Gullstrom, and L. Klareskog : Feasibility of 1 hour infliximab infusions. Ann Rheurn Dis 2005 ; 64 : 654.
 
5) 三浦靖史, 立石耕司, 高橋完靖, 林申也, 黒坂昌弘 : 関節リウマチ患者へのインフリキシマブ点滴時間は1時間に短縮可能である. 日関病誌 2009 ; 28 : 515-519.
 
6) Cheifetz, A., M. Smedley, S. Martin, M. Reiter, G. Leone, L. Mayer, and S. Plevy : The incidence and management of infusion reactions to infliximab : a large center experience. Am J Gastroenterol 2003 ; 98 : 1315-1324.
 
7) Tanaka, Y., T. Takeuchi, E. Inoue, K. Saito, N. Sekiguchi, E. Sato, M. Nawata, H. Kameda, S. Iwata, K. Amano, and H. Yamanaka : Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan : one year clinical outcomes (RECONFIRM-2). ModRheurnatol 2008 : 18 : 146-152.
 
8) St Clair, E. W., D. M. van der Heijde, J. S. Smolen, R. N. Maini, J. M. Bathon, P. Emery, E. Keystone, M. Schiff, J. R. Kalden, B. Wang, K. Dewoody, R. Weiss, and D. Baker : Combination of infliximab and methotrexate therapy for early rheumatoid arthritis : a randomized, controlled trial. Arthritis Rheum 2004 ; 50 : 3432-3443.
 
9) Goekoop-Ruiterman, Y. P., J. K. de Vries-Bouwstra, C. F. Allaart, D. van Zeben, P. J. Kerstens, J. M. Hazes, A. H. Zwinderman, H. K. Ronday, K. H. Han, M. L. Westedt, A. H. Gerards, J. H. van Groenendael, W. F. Lems, M. V. van Krugten, F. C. Breedveld, and B. A. Dijkmans : Clinical and radiographic outcomes of fbur different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) : a randomized, controlled trial. Arthritis Rheum 2005 ; 52 : 3381-3390.
 
10) Klarenbeek, N. B., M. Guler-Yuksel, S. M. van der Kooij, K. H. Han, H. K. Ronday, P. J. Kerstens, P. E. Seys, T. W. Huizinga, B. A. Dijkmans, and C. F. Allaart : The impact of fbur dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011 ; 70 : 1039-1046.
 
11) Tanaka, Y., T. Takeuchi, T. Mimori, K. Saito, M. Nawata, H. Kameda, T. Nojima, N. Miyasaka, and T. Koike : Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010 ; 69 : 1286-1291.
 
12) Takeuchi, T., Y. Tatsuki, Y. Nogami, N. Ishiguro, Y. Tanaka, H. Yamanaka, N. Kamatani, M. Harigai, J. Ryu, K. Inoue, H. Kondo, S. Inokuma, T. Ochi, and T. Koike : Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008 ; 67 : 189-194.
 
P.44 掲載の参考文献
1) Klareskog I., van der Heijde D, de Jager JP, et al : Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomised controlled trial. Lancet. 2004 ; 363 : 675-81.
PubMed
2) van der Heijde D, Klareskog L, Landewe Ret al : Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2007 ; 56 : 3928-39.
 
3) Emery P, Breedveld FC, Hall S et al : Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET) : a randomised, double-blind, parallel treatment trial. Lancet 2008 ; 372 : 375-82.
 
4) Emery P, Kvien TK, Combe B et al : Combination etanercept and methotrexate provides better disease control in very early (< 4months) versus early rheumatoid arthritis (> 4 months and < 2 years) : post hoc analyses from the COMET study. Ann Rheum Dis 2012 : 71 : 989-92
 
5) Singh JA, Furst DE, Bharat A, Curtis JR et al : 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 ; 64 : 625-39.
PubMed
6) Weinblatt ME, Bathon JM, Kremer JM et al : Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011 ; 63 : 373-82.
PubMed
7) Kameda H, Kanbe K, Sato E et al : Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis : 52-week results from the JESMR study. J Rheumatol 2011 ; 38 : 1585-92.
PubMed
8) Smolen JS, Nash P, Durez P et al : Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE) : a randomised controlled trial. Lancet 2013 ; 381 : 918-29.
PubMed
9) エンブレル適正使用情報 Vol. 9
 
10) Hetland ML, Christensen IJ, Tarp U et al : All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab : results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010 ; 62 : 22-32.
PubMed
11) Marchesoni A, Zaccara E, Gorla R et al : TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009 ; 1173 : 837-46.
 
P.51 掲載の参考文献
1) Ferdinand C. Breedveld et al : The PREMIER study : A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006 ; 54 : 26-37.
 
2) van der Heijde D et al : Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate : 5-Year Results of PREMIER. J Rheumatol 2010 ; 37 : 2237-2246.
 
3) L, Heimans et al : A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission : the IMPROVED study. Ann Rheum Dis 2013 (on line first)
 
4) Takeuchi T, et al : Effectiveness and safety of adalimumab in Japan patients with rheumatoid arthritis : retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol 2012 ; 22 : 327-338.
PubMed
5) Takeo Koike et al : Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol 2012 ; 22 : 498-508.
 
6) Geertje M Bartelds et al : Clinical response to adalimumab : relationship to antiadalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007 ; 66 : 921-926.
PubMed
7) Miyasaka N : CHANGE Study Investigators : Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation : the CHANGE study. Mod Rheumatol 2008 ; 18 : 252-262.
 
8) Krieckaert CL et al : Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012 ; 71 : 1914-1915.
 
P.56 掲載の参考文献
1) Ogata A, Yoshida Y, Morishima A, Kumanogoh A, and Tanaka T : IL-6 Target-ing Strategy for Rheumatoid Arthritis. Chapter 3, "Interleukin-6 : Genetics, Clinical Applications and Role in Disease", (pp. 111-150) Edted by D'Aquino J and Edward N. DeVito EN. Nova Science Publishers Inc. March 2013.
 
2) アクテムラ点滴静注用80mg 200mg 400mg 全例調査 最終報告 「関節リウマチ」「多関節に活動性を有する若年性特発性関節炎」
 
3) Hishitani Y, Ogata A, Shima Y, Hirano T, Ebina K, Kunugiza Y, Shi K, Narazaki M, Hagihara K, Tomita T, Yoshikawa H, Tanaka T, Kumanogoh A : Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol. 2013 ; 42 (4) : 253-259.
PubMed
4) Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N : Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol. 2014 Jan ; 24 (1) : 17-25.
PubMed
5) Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N : Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. Mod Rheumatol. 2014 Jan ; 24 (1) : 26-32.
PubMed
6) Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, Kondo M, Ueki Y, Iwahashi M, Tohma S, Ohta S, Saeki Y, Tanaka T : Musashi Study Investigators. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Mar ; 66 (3) : 344-354.
 
7) Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE : Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov ; 66 (11) : 1653-1661.
PubMed
8) Momohara S, Hashimoto J, Tsuboi H, Miyahara H, Nakagawa N, Kaneko A, Kondo N, Matsuno H, Wada T, Nonaka T, Kanbe K, Takagi H, Murasawa A, Matsubara T, Suguro T : Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting : results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol. 2013 ; 23 (3) : 440-449.
 
9) Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T : Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI) : significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009 ; 19 (1) : 12-19.
 
10) Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M : TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomised controlled trial. Lancet. 2004 ; 363 (9410) : 675-681.
PubMed
11) Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JI., Spencer-Green GT : The PREMIER study : A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006 ; 54 (1) : 26-37.
 
12) Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga TW : Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders : 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013 ; 72 (1) : 43-50.
PubMed
13) Takeuchi T, Kaneko Y, Atsumi T, Tanaka Y, Inoh M, Kobayashi H, Amano K, Miyata M, Murakawa Y, Fujii T, Kawakami A, Yamanaka H, Yamamoto K, Miyasaka N, Mimori T, Tanaka E, Nagasawa H, Yasuoka H, Hirata S : Clinical and radiographic effects after 52-week of adding tocilizumab or switching to tocilizumab in RA patients with inadequate response to methotorexate : results from a prospective randomized controlled study (SURPRISE study). Ann Rheuma Dis 2014 ; 73 (suppl 2) 686.
 
14) Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, Hansen MS, Amital H, Xavier RM, Troum O, Bernasconi C, Huizinga TW : Clinical, radiographic and immunogenic effects after lyear of tocilizumab-based treatment strategies in rheumatoid arthritis : The ACT-RAY study. Ann Rheum Dis. 2014 May ; 73 (5) : 803-809.
 
15) Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A : ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA) : a randomised, double-blind, controlled phase 4 trial. 1, ancet. 2013 ; 381 (9877) : 1541-1550.
 
16) Smolen JS. EULAR RA : management recommendations 2013 : what is new? Presented at EULAR 2013 Madrid.
 
P.62 掲載の参考文献
1) Read S et al : J Exp Med 192 : 295-302, 2000
 
2) Tivol EA et al : J Immunol 158 : 5091-5094, 1997
PubMed
3) Mandelbrot DA et al : J Exp med 189 : 435-440, 1999
PubMed
4) 日本リウマチ学会ガイドラインより
 
5) Kremer JM et al : Ann Intern Med 144 : 865-876, 2006
PubMed
6) Genovese MC et al : N Engl J Med. 353 : 1114-1123, 2005
PubMed
7) Westhovens R et al : Ann Rheum Dis 68 : 1870-1877, 2009
PubMed
8) Schiff M et al : Ann Rheum Dis 67 : 1096-1103, 2008
PubMed
9) Emery P et al : Ann Rheum Dis 69 : 510-516, 2010
PubMed
10) Sigh JA et al : The Cochrane Collaboration 2011
 
11) Smitten AL et al : Arthritis Rheum 58 : S786, 2008
 
12) Simon TA et al : Ann Rheum Dis. 68 : 1819-1826, 2009
PubMed
13) Khraishi M et al : Clin Ther 31 : 1855-1870, 2010
 
14) Haggerty HG et al : Arthritis Rheum 56 : S701, 2007
 
P.66 掲載の参考文献
1) Shealy D, et al : Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2010, 2 : 428-39.
PubMed
2) 藤井秀二他 : ゴリムマブ (シンポニー(R)) の薬理学的特徴および臨床試験成積. 日薬理誌 141 : 275-285, 2013
 
3) Tanaka Y, et al : Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis : results of the GO-FORTH study. Ann Rheum Dis. 2012, 72 : 817-24.
PubMed
4) Takeuchi T, et al : Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs : results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. Ann Rheum Dis. 2013, 72 : 1488-95.
PubMed
5) シンポニー皮下注50mg添付文書
 
P.71 掲載の参考文献
1) Palframan R, Airey M, Moore A, Vugler A, Nesbitt A : Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009 ; 348 : 36-41.
PubMed
2) Keystone E, Heijde Dv, Mason D Jr, Landewe R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K : Certolizumab pegol plus meth. otrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis : findings of a fifty-twoweek, phase III, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study. Arthritis Rheum. 2008 ; 58 : 3319-29.
 
3) Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff M, Burmester GR, Strand V, Vencovsky J, van der Heijde D : Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis : the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009 : 68 : 797-804.
PubMed
4) Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V : Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy : the FAST4WARD study. Ann Rheum Dis. 2009 ; 68 : 805-11.
PubMed
5) Wakefield I, Stephens S, Foulkes R, Nesbitt A, Bourne T : The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibody. Toxicol Sci. 2011 ; 122 : 170-6.
PubMed
6) Keystone E, I. andewe R, van Vollenhoven R, Combe B, Strand V, Mease P, Shaughnessy L, Vanlunen B, van der Heijde D : Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis : 5-year results from the RAPID 1 trial and open-1abel extension. Ann Rheum Dis. (in press)
 
P.76 掲載の参考文献
1) Mease P, Strand V, Shalamberidze L, et al : A phase H, double-blind, randomized, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012 : 71 : 1183-1189.
 
2) Pavelka K, et al : A randomized, double-blind, placebo・controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheum 64 (10, suppl) : S362, 2012.
 
3) Genovese MC, Durez P, Richards HB, et al : Efficacy and safety of secukinumab in patients with rheumatoid arthritis : a phase H, dose-finding, double-blind, randomized, placebo controlled study. Ann Rheum Dis 2013 ; 72 : 863-869.
 
4) Genovese MC, van den Bosch F, Roberson SA, et al : LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. A phase I randomized, doubleblind, placebo-controlled, proof-of concept study. Arthritis Rheum 2010 ; 62 : 929-939.
PubMed
5) Hsu Y-H, Chang M-S : Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum 2010 ; 62 : 3311-3321.
PubMed
6) SEnolt L, et al : Clinical responses and patient reported outcomes to NNC0109-0012 (anti-IL-20 mAb) in rheumatoid arthritis (RA) patients fbllowing 12-weeks dosing and 13 weeks follow up : Results from a phase 2a trial. Arthritis Rheum 64 (10, suppl) : S364, 2012.
 
7) Burmester GR, Feist E, Sleeman MA, et al : Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis : a randomized, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 70 (9) : 1542-1549, 2011.
 
8) Burmester GR, Weinblatt ME, McInnes IB, et al : Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis (in press).
 
9) Hahn BH : Belimumab for systemic lupus erythematosus. N Engl J Med 2013 ; 368 : 1528-1535.
PubMed

第3章 関節リウマチにおける生物学的製剤と他の薬剤との併用

P.82 掲載の参考文献
1) Pincus T, et al : Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 2003 ; 21 (Suppl 31) : S179-185
 
2) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update. Ann Rheum Dis 2014 ; 73 : 492-509
 
3) 関節リウマチ治療におけるMTX診療ガイドライン : 日本リウマチ学会MTX診療ガイドライン策定小委員会編, 羊土社, 2011. 3
 
4) Haraoui B, et al : Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA) : Results from the CanACT study. BMC Muscloskel Dis 2011 ; 12 : 261-270
 
5) Weinblatt ME, et al : Efficacy and safety of certolizmab pegol in a broad population of patients with active rheumatoid arthritis : results from the REAI. ISTIC phase IIIb study. Rherumatology (Oxford) 2012 ; 51 : 2204-14
 
6) Breedveld FC, et al : The PREMIER study. A multicenter, randomized, doubleblind clinical trial of combination therapy with adalimjmab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis whou had not had previous methotreaxte treatment. Arthritis Rheum 2006 ; 54 : 26-37
PubMed
7) Klareskog, et al : Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomised controlled trial-Lancet 2004 ; 363 : 675-81
PubMed
8) van der Heijde D, et al : Comparison of Etanercept and Methotrexate, Alone and Combined, in the Treatment of Rheumatoid Arthritis. Two-Year Clinical and Radiographic Results from the TEMPO Study, a Double-Blind, Randomized Trial. Arthritis Rheum 2006 ; 54 : 1063-1074
 
9) van der Heijde D, et al : Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis : the TEMPO trial. Ann Rheum Dis 2006 ; 65 : 328-34.
 
10) van Riel PL, Add Enbrel or Replace Methotrexate Study Investigators. et al : Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate : the ADORE study. Ann Rheum Dis 2006 ; 65 : 1478-83.
PubMed
11) Kremer J, et al : Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis : Forty-eight-week ef6cacy and safety results of a phase III randomized, doubleblind, placebo-controlled study. Arthritis Rheum 2010 ; 62 : 917-28.
PubMed
12) Kameda H, et al : Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy : a randomized trial. Mod Rheumatol 2010 ; 20 : 531-538
 
13) Maini RN, et al : Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist tocilizumab in Eurpean patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006 ; 54 : 2817-29.
 
14) Dougados M, et al : Adding tocilizumab or switching to tocilizumabmonotherapy in methotrexate inadequate responders : 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013 ; 72 : 43-50.
 
15) Emery P, et al : Evaluating drug-free remission with abatacept in early rheumatoid arthritis : results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 2015 ; 74 : 19-26
 
16) Soliman MM, et al : Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis : results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011 ; 70 : 583-89
 
17) Tanaka Y, et al : Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010 ; 69 : 1286-91.
PubMed
18) Smolen JS, et al : Maintenance, reduction, or withdraw al of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE) : a randomised controlled trial. Lancet 2013 ; 381 : 918-29
 
P.89 掲載の参考文献
1) 川合眞一編 : 「研修医のためのステロイドの使い方のコツ」, 文光堂, 東京, 2009 (4月)
 
2) Kirwan JR : The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995 : 333 : 142-146.
 
3) Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I : Lowdose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate : a two-year randomized trial. Arthritis Rheum. 2005 ; 52 : 3360-3370.
 
4) Wassenberg S, Rau R, Steinfeld P, Zeidler H : Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years : a multicenter, double-blind, Placebo-controlled trial. Arthritis Rheum. 2005 ; 52 : 3371-3380.
 
5) Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA : Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study) : a randomized, controlled trial. Arthritis Rheum. 2005 ; 52 : 3381-3390.
PubMed
6) 川合眞一 : 副腎皮質ステロイド. 「今日の治療薬 2014」 (編集 : 浦部晶夫, 島田和幸, 川合眞一), pp. 239-246, 南江堂, 東京, 2014.
 
7) Wolfe F, Caplan L, Michaud K : Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia : associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006 ; 54 : 628-634.
PubMed
8) Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, Listing J : Treatment benefit or survival of the fittest : what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011 ; 70 : 1914-1920.
PubMed
9) Harigai M, Koike R, Miyasaka N : Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007 ; 357 : 1874-1876.
 
10) 日本リウマチ学会 : B型肝炎ウイルス感染リウマチ性疾患, 患者への免疫抑制療法に関する提言. http://www.ryumachi-jp.com/infb/news120905.pdf
 
11) The Epidemiology Program Office, Centers for Disease Control and Prevention (CDC) : General Recommendations on Immunization. http://www.cdc.gov/MMWR/PDF/RR/RR5102.pdf
 
12) 金子開知, 川合眞一 : グルココルチコイド誘発性骨粗鬆症の病態と治療. 日本臨床免疫学会会誌 2011 ; 34 : 138-148.
Medical*Online
13) Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R : Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis : a twelve-month, multicenter, randomized, double-blind, Placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008 ; 58 : 1299-1309.
 
14) Okano T, Koike T, Tada M, Sugioka Y, Mamoto K, Wakitani S, Nakamura H : The limited effects of anti. tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid. J Bone Miner Metab. 2013 Nov 15 [Epub ahead of print]
 
15) Aoki K, Kawai S : Glucocorticoid therapy decreases serum lipoprotein (a) concentration in rheumatic diseases. Intern Med. 1993 ; 32 : 382-386.
PubMed
16) Daien CI, Duny Y, Barnetche T, Daures JP, Combe B, Morel J : Effect of TNF inhibitors on lipid profile in rheumatoid arthritis : a systematic review with metaanalysis. Ann Rheum Dis. 2012 ; 71 : 862-868.
PubMed
17) Nishimoto N, Ito K, Takagi N : Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis : meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010 ; 20 : 222-232.
PubMed
P.96 掲載の参考文献
1) Smolen JS, Landewe R, Breedveld FC et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69 : 964-975, 2010.
PubMed
2) Singh JA, Furst DE, Bharat A et al : 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64 : 625-639, 2012.
PubMed
3) NSAIDsの選び方・使い方ハンドブック. 佐野統編, 羊土社, 東京, 2010.
 
4) 佐野統 : 非ステロイド抗炎症薬 (COX-2 阻害薬). 日内会誌 100 : 2888-2901, 2011.
 
5) COX-2阻害薬の適正使用. 佐野統編, フジメディカル出版, 大阪, 2012.
 
6) 薬物性潰瘍. 消化性潰瘍診療ガイドライン. 日本消化器病学会編, 南江堂, 東京, pp91-117, 2009.
 
7) Emery P, Zeidler H, Kvien TK et al : Celecoxib versus diclofenac in long-term management of rheumatoid arthritis : randomized double-blind comparison. Lancet 354 : 2106-2111, 1999.
PubMed
8) Kusunoki N, Yamazaki R, Kawai S : Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum 46 : 3159-3167, 2002.
PubMed
9) 高崎芳成 : 第3章 非ステロイド系消炎鎮痛薬 (NSAIDs). 診断のマニュアルとEBMに基づく治療ガイドライン (改訂版). 厚生労働省研究班編, 日本リウマチ財団, 東京, pp71-77, 2004,
 
10) 東直人, 佐野統 : 整形外科・リウマチ疾患におけるNSAIDsの使用と消化管障害の対策. 消臨 16 : 136-141, 2013.
 
11) 塩川優一, 延永正, 斉藤輝信ほか. 非ステロイド性抗炎症剤による上部消化管障害に関する疫学調査. リウマチ 31 : 96-111, 1991.
 
12) Graham DY, Opekun AR, Willingham FF, et al : Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroentrerol Hepatol. 3 : 55-59, 2005.
PubMed
13) 蔵原晃一, 松本主之, 飯田三雄 : 大腸粘膜障害の診断と臨床的特徴. 日本臨牀 69 : 1098-1103, 2011.
 
14) Wolfe MM, Lichtenstein DR, Singh G : Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 340 : 1888-1899, 1999.
PubMed
15) Scheiman JM : Unmet needs in non-steroidal anti-inflammatory Drug-induced upper gastrointestinal diseases. Drugs 66 Suppl 1 : 15-21, 2006.
 
16) 東直人, 佐野統 : 関節リウマチ. 日内会誌 100 : 1237-1243, 2011.
 
17) 東直人, 佐野 統 : 疼痛管理の重要性とNSAIDsの位置づけをみる. 整形外科診療のためのNSAIDs処方ハンドブック～NSAIDs処方と潰瘍対策の実際～ 岩本幸英, 菅野健太郎編先端医学社, 東京, pp14-22, 2012.
 
18) Sakamoto C, Kawai T, Nakamura S et al : Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy : a placebo-controlled, double-blind 2-week study. Aliment Pharmacol Ther 37 : 346-354, 2013.
PubMed
19) Weideman RA, Kelly KC, Kazi S et al : Risks of clinically significant upper gastrointestinal events with etodolac and naproxen : a historical cohort analysis. Gastroenterology 127 : 1322-1328, 2004.
PubMed
20) Chan FK, Lanas A, Scheiman J et al : Celecoib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR) : a randomized trial. Lancet 376 : 173-179, 2010.
 
21) 村島温子 : 解熱・鎮痛・抗炎症薬. 妊娠と授乳. 伊藤真也, 村島温子編, 南山堂, 東京, pp185-190, 2010.
 
22) 田中菜穂子, 川合眞一 : 関節リウマチ, 膠原病の妊娠時にはどのような薬剤が使用できるか? 分子リウマチ治療 6 : 15-19, 2013.
Medical*Online
23) 古川加奈子, 前島悦子, 一ノ瀬正和 : エタネルセプト投与下で妊娠・出産した関節リウマチの一例. 日臨免誌 36 : 47-51, 2013.
 
24) 関節リウマチ (RA) に対するTNF阻害薬使用ガイドライン (2014年6月29日改訂版) ; http://www.ryumachi-jp.com/info/guidelineTNF.html
 
25) Mahadevan U, Wolf DC, Dubinsky M, et al : Placental transfer of antitumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 11 : 286-292, 2013.
PubMed
P.100 掲載の参考文献
1) Schellekens H : When biotech proteins go off-patent. TRENDS in Biotechnology 2004 ; 8 : 406-410.
PubMed
2) European Medicines Agency : Guideline on similar biological medicinal products containing biotechnology. derived proteins as active substance : quality issues. 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf
 
3) US Food and Drug Administration : Quality considerations in demonstrating biosimilarity to a reference product : draft guidance February 2012. http://www.fda.gov/downloads/Drugs/GuidanceCompliance-RegulatoryInformation/Guidances/UCM291134.pdf.
 
4) Dorner T, Strand Vibeke, Castafieda-Herendez G, et al : The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013 ; 72 : 322-328.
 
5) McKoy JM, Stonecash RE, Cournoyer D, et al : Epoetin-associated pure red cell aplasia : past, present, and future considerations. Transfusion 2008 ; 48 : 1754-1762.
PubMed
6) Yoo DH, Hrycaj P, Miranda P, et al : A randomized, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis : the PLANETRA study. Ann Rheum Dis 2013 (in press).
 
7) Park W, Hrycaj P, Jeka S, et al : A randomized, double-blind, multicenter, parallel-group, prospective comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis : the PLANETAS study. Ann Rheum Dis 2013 (in, press).
 
P.107 掲載の参考文献
1) Tanaka Y, Takeuchi T, Mimori T et al : Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 69 : 1286-91, 2010.
PubMed
2) Takeuchi T, Miyasaka N, Inoue K et al : Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis : results from the RISING study. Mod Rheumatol. 19 : 478-87, 2009.
 
3) Smolen JS et al : ACR 75th Annual Scientific Meeting, 2011, Chicago, IL, L1.
 
4) Emery P, et al : EULAR 2011, Abst. No. THUO251b.
 
5) Harigai M, Takeuchi T, Tanaka Y et al : Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol. 22 (6) : 814-22, 2012.
PubMed
6) Nishimoto N, Japanese MRA Study Group for RA : Drug free remission after cessation of actemra monotherapy (DREAM STUDY). Ann Rheum Dis. 2010 ; 69 [Suppl 3] 98.
 
7) Takeuchi T : Abatacept Biologic-Free Remission Study in Established Rheumatoid Arthritis Patients. Orion Study. ACR 2012 Abstract# : 1289.
 
P.111 掲載の参考文献
1) Louie GH, Ward MM : Changes in the rates of joint surgery among Patients with rheumatoid arthritis in California, 1983-2007. Ann Rheum Dis 2010 : 69 : 868-871.
PubMed
2) Sokka T, Kautiainen H, Hannonen P : Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003 : an indication of improved long-term outcomes of rheumatoid arthritis. Ann Rheum Dis 2007 ; 66 : 341-344.
PubMed
3) Momohara S, Tanaka S, Nakamura H, Mibe J, Iwamoto T, Ikari K, et al : Recent trends in orthopedic surgery performed in Japan for rheumatoid arthritis. Mod Rheumatol 2011 ; 21 : 337-342.
PubMed
4) Seki E, Matsushita I, Sugiyama E, Taki H, Shinoda K, Hounoki H, et al : Radiographic progression in weight-bearing joints of patients with rheumatoid arthritis after TNF-blocking therapies. Clin Rheumatol 2009 ; 28 : 453-460.
PubMed
5) Momohara S, Ikari K, Kawakami K, Iwamoto T, Inoue E, Yano K, et al : The increasing disease duration of patients at the time of orthopaedic surgery for rheumatoid arthritis. Rheumatol Int 2012 ; 32 : 3323-3324.
PubMed
6) Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, et al : Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol 2010 ; 29 : 495-500.
PubMed
7) Hayashi M, Kojima T, Funahashi K, Kato D, Matsubara H, Shioura T, et al : Effect of total arthroplasty combined with antitumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis. Mod Rheumatol 2012 ; 22 : 363-369.
PubMed
8) Momohara S, Inoue E, Ikari K, Yano K, Tokita A, Suzuki T, et al : Efficacy of total joint arthroplasty in patients with established rheumatoid arthritis : improved longitudinal effects on disease activity but not on health-related quality of life. Mod Rheumatol 2011 ; 21 : 476-481.
 
9) Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP : Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy : results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006 ; 54 : 2368-2376.
PubMed
10) Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al : Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006 ; 55 : 333-337.
PubMed
11) Scherrer CB, Mannion AF, Kyburz D, Vogt M, Kramers-de Quervain IA : Infection risk after orthopaedic surgery in patients with inflammatory rheumatic diseases treated with immunosuppressive drugs. Arthritis Care Res (Hoboken) 2013.
 

第4章 関節リウマチにおける生物学的製剤処方事例

P.126 掲載の参考文献
1) Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M : TEMPO (Trial of Etallercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis : double-blind randomised controlled trial. Lancet. 2004 Feb 28 ; 363 (9410) : 675-81.
 
2) Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstrom DC, Blom M : Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012 ; 7 (1) : e30275. Epub 2012 Jan 17.
 
3) Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P : Biologics for rheumatoid arthritis : an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009 Oct 7 ; (4)
 
4) van Dartel SA, Fransen J, Kevit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL : Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept : results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis. 2013 Jun ; 72 (6) : 895-900.
 
5) Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B : Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE) : a randomised controlled trial. Lancet. 2013 Mar 16 ; 381 (9870) : 918-29.
PubMed
P.130 掲載の参考文献
1) Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, et al : Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis : the HOPEFUL 1 study. Ann Rheum Dis. in Press
 
2) Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al : The PREMIER study : A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 : 26-37, 2006
 
3) Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al : Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69 : 1286-91. 2010
PubMed
4) Detert J, Bastian H, Listing J, WeiB A, Wassenberg S, Liebhaber A, et al : Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARDnaive patients with early rheumatoid arthritis : HIT HARD, an investigator-initiated study. Ann Rheum Dis 72 : 844-50. 2013
 
5) Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al : Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis : 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 72 : 64-71. 2013
PubMed
6) Harigai M, Takeuchi T, Tanaka Y, Matsubara T, Yamanaka H, Miyasaka N : Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Mod Rheumatol 22 : 814-22. 2012
PubMed
7) Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, et al : Discontinuation of adalimumab after attaining DAS28 (ESR) remission in patients with rheumatoid Arthritis (HONOR study) : an observational study. Arthritis Res Ther. in press
 
P.136 掲載の参考文献
1) Smolen, J. S., et al : Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebocontrolled, randomised trial. The Lancet, 2008. 371 (9617) : p. 987-997.
 
2) Karsdal, M. A., et al : IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy : biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum, 2012. 42 (2) : p. 131-9.
PubMed
3) Schoels, M. M., et al : Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases : systematic literature review and metaanalysis informing a consensus statement. Ann Rheum Dis, 2013. 72 (4) : p. 583-9.
 
4) Dougados, M., et al : Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders : 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis, 2013. 72 (1) : p. 43-50.
 
5) Burmester, G., et al : Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in MTX-naive patients with early rheumatoid arthritis (RA) : clinical and radiographic outcomes from a randomised, placebo-controlled trial. Ann Rheum Dis, 2013. 72 (Suppl 3).
 
6) Takeuchi, T., et al : Adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate : 24-week results from a randomized controlled study (SURPRISE study). Ann Rheum Dis, 2013. 72 (Suppl 3).
 
7) Nishimoto, N., et al : Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI) : significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol, 2009. 19 (1) : p. 12-9.
 
8) Jones, G., et al : Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis : he AMBITION study. Ann Rheum Dis, 2010. 69 (1) : p. 88-96.
 
9) Ogata, A., et al : Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord, 2012. 5 : p. 27-42.
 
10) Garnero, P., et al : Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate : results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum, 2010. 62 (1) : p. 33-43.
PubMed
11) Nishimoto, N., et al : Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol, 2013.
 
12) Huizinga, T. W. J., et al : Clinical and radiographic outcomes at two years and the effect of tocilizumab (TCZ) discontinuation following sustained remission in the second year of the ACT-RAY study. Ann Rheum Dis, 2013. 72 (Suppl 3).
 
13) Nishimoto, N., et al : Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. Mod Rheumatol, 2013.
 
14) Koike, T., et al : Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan : interim analysis of 3881 patients. Ann Rheum Dis, 2011. 70 (12) : p. 2148-51.
 
15) Hishitani, Y., et al : Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol, 2013. 42 (4) : p. 253-9.
 

書評

最近チェックした商品履歴

Loading...